(FMC) FMC - Overview
Sector: Basic Materials | Industry: Agricultural Inputs | Exchange: NYSE (USA) | Market Cap: 1.639m USD | Total Return: -63.8% in 12m
Avg Turnover: 35.5M
EPS Trend: -53.3%
Qual. Beats: -1
Rev. Trend: -90.7%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -0.2 is critical
Below Avwap Earnings
Tailwinds
No distinct edge detected
FMC Corporation is a Philadelphia-based agricultural sciences company specializing in the development and distribution of crop protection chemicals, including insecticides, herbicides, and fungicides. Founded in 1883, the firm maintains a global footprint with operations across North America, Latin America, Europe, the Middle East, Africa, and Asia.
The company operates within the Fertilizers & Agricultural Chemicals sub-industry, a sector characterized by high research and development costs and rigorous regulatory oversight for product safety. FMC utilizes a diversified distribution model, leveraging internal sales organizations alongside alliance partners and independent distributors to reach regional markets.
To better understand the companys competitive positioning and valuation metrics, consider reviewing the detailed financial breakdowns available on ValueRay. In addition to traditional synthetics, FMC has expanded its portfolio into biologicals and seed treatments to address increasing global demand for sustainable farming solutions.
- Latin American agricultural demand drives seasonal revenue growth and cash flow
- Patent expirations on core Diamides products increase generic market competition
- Global inventory destocking cycles impact volume recovery and pricing power
- Raw material cost fluctuations and manufacturing efficiency influence operating margins
- Regulatory scrutiny of crop protection chemicals affects product registration timelines
| Net Income: -2.50b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -2.99 > 1.0 |
| NWC/Revenue: 31.78% < 20% (prev 43.02%; Δ -11.24% < -1%) |
| CFO/TA -0.01 > 3% & CFO -138.5m > Net Income -2.50b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (125.3m) vs 12m ago 0.18% < -2% |
| Gross Margin: 35.31% > 18% (prev 0.39%; Δ 3.49k% > 0.5%) |
| Asset Turnover: 32.37% > 50% (prev 34.91%; Δ -2.54% > 0%) |
| Interest Coverage Ratio: -0.24 > 6 (EBITDA TTM -222.5m / Interest Expense TTM 1.64b) |
| A: 0.12 (Total Current Assets 4.90b - Total Current Liabilities 3.81b) / Total Assets 9.42b |
| B: 0.41 (Retained Earnings 3.88b / Total Assets 9.42b) |
| C: -0.04 (EBIT TTM -390.9m / Avg Total Assets 10.6b) |
| D: 0.47 (Book Value of Equity 3.57b / Total Liabilities 7.57b) |
| Altman-Z'' = 2.35 = BBB |
| DSRI: 0.93 (Receivables 2.24b/2.90b, Revenue 3.43b/4.12b) |
| GMI: 1.10 (GM 35.31% / 38.92%) |
| AQI: 0.83 (AQ_t 0.41 / AQ_t-1 0.50) |
| SGI: 0.83 (Revenue 3.43b / 4.12b) |
| TATA: -0.25 (NI -2.50b - CFO -138.5m) / TA 9.42b) |
| Beneish M = -3.47 (Cap -4..+1) = AA |
As of May 30, 2026, the stock is trading at USD 13.66 with a total of 2,088,131 shares traded.
Over the past week, the price has changed by +5.00%,
over one month by -6.76%,
over three months by -6.88% and
over the past year by -63.78%.
FMC has received a consensus analysts rating of 3.55. Therefore, it is recommended to hold FMC.
- StrongBuy: 5
- Buy: 2
- Hold: 12
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 17.3 | 26.3% |
P/E Forward = 7.9808
P/S = 0.4773
P/B = 0.8928
P/EG = 1.5465
Revenue TTM = 3.43b USD
EBIT TTM = -390.9m USD
EBITDA TTM = -222.5m USD
Long Term Debt = 2.77b USD (from longTermDebt, last quarter)
Short Term Debt = 1.79b USD (from shortTermDebt, last quarter)
Debt = 4.78b USD (from shortLongTermDebtTotal, last quarter) + Leases 123.9m
Net Debt = 4.39b USD (calculated: Debt 4.78b - CCE 390.9m)
Enterprise Value = 6.03b USD (1.64b + Debt 4.78b - CCE 390.9m)
Interest Coverage Ratio = -0.24 (Ebit TTM -390.9m / Interest Expense TTM 1.64b)
EV/FCF = -48.82x (Enterprise Value 6.03b / FCF TTM -123.5m)
FCF Yield = -2.05% (FCF TTM -123.5m / Enterprise Value 6.03b)
FCF Margin = -3.60% (FCF TTM -123.5m / Revenue TTM 3.43b)
Net Margin = -72.93% (Net Income TTM -2.50b / Revenue TTM 3.43b)
Gross Margin = 35.31% ((Revenue TTM 3.43b - Cost of Revenue TTM 2.22b) / Revenue TTM)
Gross Margin QoQ = 32.51% (prev 42.50%)
Tobins Q-Ratio = 0.64 (Enterprise Value 6.03b / Total Assets 9.42b)
Interest Expense / Debt = 34.37% (Interest Expense 1.64b / Debt 4.78b)
Taxrate = 21.0% (US default 21%)
NOPAT = -308.8m (EBIT -390.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.29 (Total Current Assets 4.90b / Total Current Liabilities 3.81b)
Debt / Equity = 2.62 (Debt 4.78b / totalStockholderEquity, last quarter 1.82b)
Debt / EBITDA = -19.73 (negative EBITDA) (Net Debt 4.39b / EBITDA -222.5m)
Debt / FCF = -35.54 (negative FCF - burning cash) (Net Debt 4.39b / FCF TTM -123.5m)
Total Stockholder Equity = 3.02b (last 4 quarters mean from totalStockholderEquity)
RoA = -23.61% (Net Income -2.50b / Total Assets 9.42b)
RoE = -83.04% (Net Income TTM -2.50b / Total Stockholder Equity 3.02b)
RoCE = -6.76% (EBIT -390.9m / Capital Employed (Equity 3.02b + L.T.Debt 2.77b))
RoIC = -4.19% (negative operating profit) (NOPAT -308.8m / Invested Capital 7.37b)
WACC = 22.35% (E(1.64b)/V(6.42b) * Re(8.33%) + D(4.78b)/V(6.42b) * Rd(34.37%) * (1-Tc(0.21)))
Discount Rate = 8.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -22.36 | Cagr: -0.35%
[DCF] Fair Price = unknown (Cash Flow -123.5m)
EPS Correlation: -53.27 | EPS CAGR: -15.08% | SUE: -4.0 | # QB: -1
Revenue Correlation: -90.68 | Revenue CAGR: -12.58% | SUE: 0.07 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.21 | Chg30d=-53.08% | Revisions=-67% | Analysts=15
EPS next Quarter (2026-09-30): EPS=0.67 | Chg30d=-1.69% | Revisions=+0% | Analysts=15
EPS current Year (2026-12-31): EPS=1.72 | Chg30d=-2.93% | Revisions=-26% | GrowthEPS=-42.0% | GrowthRev=+6.6%
EPS next Year (2027-12-31): EPS=2.20 | Chg30d=-2.10% | Revisions=-22% | GrowthEPS=+28.4% | GrowthRev=+4.4%
[Analyst] Revisions Ratio: -67%